ZVRA
Zevra Therapeutics Inc.
10.70$
+7.1%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -65.8% | +18.3% | +29.9% | -16.9% | +225.9% | +69.4% | +26.9% | +0.7% | +30.9% | +6.1% | +9.5% | – | |
| – | -78.7% | +2,167.4% | +9.4% | -35.5% | -40.7% | -1.5% | +820.4% | -87.5% | -2.1% | +49.0% | -32.7% | – | |
| – | -64.7% | -94.2% | +447.5% | +58.9% | +667.0% | +78.5% | -29.1% | +81.5% | +33.0% | +4.1% | +12.3% | – | |
| – | +65.4% | -12.9% | -1.8% | +4.0% | -9.4% | -67.1% | +5.4% | 0.0% | -23.7% | +67.6% | +2.1% | – | |
| – | -16.9% | +70.7% | -83.8% | +910.5% | -90.1% | +1,118.5% | +6.3% | -18.5% | +20.2% | +2.1% | -20.3% | – | |
| – | +29.0% | +14.0% | +19.5% | +16.3% | -9.1% | -6.4% | +246.2% | -75.9% | +14.4% | +8.1% | -15.1% | – | |
| – | – | – | – | – | – | – | – | – | +124.8% | -5.2% | +90.0% | – | |
| – | +85.8% | +100.8% | +187.1% | +9.6% | -5.1% | -10.3% | +2.0% | +2.1% | -5.0% | -12.2% | -100.0% | – | |
| – | – | – | – | – | – | – | – | -101.3% | – | +253.7% | -71.4% | – | |
| – | – | -139.5% | – | – | – | -92.3% | +86.0% | -119.7% | – | +1,280.0% | -41.5% | – | |
| – | – | – | – | – | – | – | – | -100.7% | – | +211.5% | -76.9% | – | |
| – | – | – | – | – | – | – | +4,636.4% | -98.2% | +921.6% | +190.2% | -69.8% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.